Gaetan Duport: The Next Challenge for Patient Involvement at EMA
Gaetan Duport, User Representative on the Economic and Public Health Committee (CEESP) at French National Authority for Health, shared on LinkedIn:
”EMA’s 2024–2025 stakeholder report is worth reading closely from a patient involvement perspective.
Patient participation at EMA is becoming more embedded in procedure, not just consultation.
The Agency revised its CHMP public assessment report template to reflect patient input and patient experience data, introduced a form to capture patient input in scientific advice, and expanded the PCWP from 22 to 25 organisations.
But the report also confirms something patient organisations know very well: meaningful participation is resource-intensive.
In 2024, 70 patients and carers contributed to 67 procedures; in 2025, 53 contributed to 53.
By December 2025, EMA had 42 eligible patient and consumer organisations.
That is real influence — but it also points to a small, highly mobilised ecosystem carrying a heavy operational load.
This is why the 2025 mobilisation on voting rights mattered.
More than 70 additional patient organisations joined EPF and EURORDIS in calling for meaningful patient involvement and retention of voting rights.
EMA’s Management Board minutes later noted with satisfaction that patient priorities, including voting rights, had been included — while also warning that participation depends on a very small pool of people and requires adequate support.
The real issue in 2026 is no longer only recognition in principle.
It is follow-up: capacity, continuity, support, and the ability of patient organisations to remain present where decisions are actually shaped and budget cut.
The General Pharmaceutical Legislation is expected to come into late 2026, followed by a Lon transition period.”

Stay updated with Hemostasis Today.
-
Jun 28, 2026, 04:45Abolfazl Miri: Improving ITP Diagnosis with Readily Available Hematological Indices
-
Jun 28, 2026, 04:22Jensa Morris: Why Low Molecular Weight Heparins Should Be the First Choice for VTE
-
Jun 28, 2026, 03:57Sara Zalghout: Navigating the Often-Unspoken Challenges of Academia at ISTH 2026
-
Jun 28, 2026, 02:56Carlo Alfieri: Redefining Anemia Management After Kidney Transplantation
-
Jun 28, 2026, 02:36Ramesh Chennupat: Anemia is Associated with Increased REV Release in Stable Coronary Artery Disease
-
Jun 28, 2026, 02:01RishiRaj Sinha: Driving the Future of Transfusion Medicine Through Global Collaboration at ISBT 2026
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention